These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 24750110)
1. Novel therapeutic targets in myeloma bone disease. Webb SL; Edwards CM Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110 [TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate therapy in the treatment of multiple myeloma. Lawson MA; Ashcroft J; Croucher PI Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619 [TBL] [Abstract][Full Text] [Related]
3. Emerging treatment approaches for myeloma-related bone disease. Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic approaches to myeloma bone disease: an evolving story. Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965 [TBL] [Abstract][Full Text] [Related]
5. Management of bone disease in multiple myeloma. Terpos E; Berenson J; Raje N; Roodman GD Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088 [TBL] [Abstract][Full Text] [Related]
6. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma. Yee AJ; Raje NS Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis and management of myeloma bone disease. Christoulas D; Terpos E; Dimopoulos MA Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944 [TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897 [TBL] [Abstract][Full Text] [Related]
10. Optimal use of bisphosphonates in patients with multiple myeloma. Terpos E; Roodman GD; Dimopoulos MA Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550 [No Abstract] [Full Text] [Related]
11. Anti-tumour activity of bisphosphonates in human myeloma cells. Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI Leuk Lymphoma; 1998 Dec; 32(1-2):129-38. PubMed ID: 10037008 [TBL] [Abstract][Full Text] [Related]
12. Biology and treatment of myeloma related bone disease. Terpos E; Christoulas D; Gavriatopoulou M Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022 [TBL] [Abstract][Full Text] [Related]
13. Myeloma bone disease: pathogenesis, current treatments and future targets. Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762 [TBL] [Abstract][Full Text] [Related]
14. An Evidence-Based Approach to Myeloma Bone Disease. Bingham N; Reale A; Spencer A Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849 [TBL] [Abstract][Full Text] [Related]
15. Advances in the biology and treatment of bone disease in multiple myeloma. Raje N; Roodman GD Clin Cancer Res; 2011 Mar; 17(6):1278-86. PubMed ID: 21411443 [TBL] [Abstract][Full Text] [Related]
17. Bone disease in multiple myeloma. Hjertner Ø; Standal T; Børset M; Sundan A; Waage A Med Oncol; 2006; 23(4):431-41. PubMed ID: 17303901 [TBL] [Abstract][Full Text] [Related]
18. Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. Pochintesta L; Mangiacavalli S; Cocito F; Pompa A; Albertini R; Pascutto C; Ferretti VV; Cazzola M; Corso A Leuk Lymphoma; 2014 Jun; 55(6):1397-8. PubMed ID: 23931337 [No Abstract] [Full Text] [Related]
19. [Bone disease in multiple myeloma]. Irisawa H Nihon Rinsho; 2015 Jan; 73(1):42-6. PubMed ID: 25626302 [TBL] [Abstract][Full Text] [Related]
20. Role of the bone marrow microenvironment in multiple myeloma. Roodman GD J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]